ARCUTIS BIOTHERAPEUTICS, INC. Operating Cash Flow
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Operating Cash Flow of $14.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $12.64M, a 3800.93% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $2.24M.
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $26.18M.
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.75M.
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$5.63M.
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$112.16M.
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$247.06M.
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$257.71M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $14.88M 10-Q · filed 2026-08-05 | $41.06M derived: sum of 3 quarters · filed 2026-08-05 | $39.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.24M 10-Q · filed 2026-05-06 | $28.42M derived: sum of 2 quarters · filed 2026-05-06 | $26.67M derived: sum of 3 quarters · filed 2026-05-06 | $26.99M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $26.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $24.43M derived: sum of 2 quarters · filed 2026-02-25 | $24.75M derived: sum of 3 quarters · filed 2026-08-05 | -$5.63M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$1.43M derived: sum of 2 quarters · filed 2026-08-05 | -$31.81M 10-Q · filed 2025-10-28 | -$32.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $324.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$30.06M 10-Q · filed 2026-08-05 | -$30.80M derived: sum of 3 quarters · filed 2026-08-05 | -$65.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$30.38M 10-Q · filed 2026-05-06 | -$31.13M derived: sum of 2 quarters · filed 2026-05-06 | -$65.82M derived: sum of 3 quarters · filed 2026-05-06 | -$110.94M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$748.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$35.44M derived: sum of 2 quarters · filed 2026-02-25 | -$80.56M derived: sum of 3 quarters · filed 2026-02-25 | -$112.16M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$34.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$79.81M derived: sum of 2 quarters · filed 2025-10-28 | -$111.41M 10-Q · filed 2025-10-28 | -$167.65M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$45.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$76.72M 10-Q · filed 2025-08-06 | -$132.97M derived: sum of 3 quarters · filed 2026-02-25 | -$176.95M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$31.60M 10-Q · filed 2025-05-06 | -$87.85M derived: sum of 2 quarters · filed 2026-02-25 | -$131.83M derived: sum of 3 quarters · filed 2026-02-25 | -$198.32M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$56.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$100.23M derived: sum of 2 quarters · filed 2026-02-25 | -$166.71M derived: sum of 3 quarters · filed 2026-02-25 | -$247.06M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$43.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$110.47M derived: sum of 2 quarters · filed 2024-11-06 | -$190.81M 10-Q · filed 2024-11-06 | -$261.88M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$66.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$146.83M 10-Q · filed 2024-08-14 | -$217.89M derived: sum of 3 quarters · filed 2025-02-25 | -$285.59M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$80.34M 10-Q · filed 2024-05-14 | -$151.41M derived: sum of 2 quarters · filed 2025-02-25 | -$219.10M derived: sum of 3 quarters · filed 2025-02-25 | -$281.08M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$71.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$138.76M derived: sum of 2 quarters · filed 2025-02-25 | -$200.74M derived: sum of 3 quarters · filed 2025-02-25 | -$257.71M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$67.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$129.68M derived: sum of 2 quarters · filed 2023-11-03 | -$186.65M 10-Q · filed 2023-11-03 | -$238.36M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$61.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$118.95M 10-Q · filed 2023-08-08 | -$170.66M derived: sum of 3 quarters · filed 2024-02-27 | -$211.55M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$56.98M 10-Q · filed 2023-05-09 | -$108.68M derived: sum of 2 quarters · filed 2024-02-27 | -$149.57M derived: sum of 3 quarters · filed 2024-02-27 | -$185.40M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$51.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$92.59M derived: sum of 2 quarters · filed 2024-02-27 | -$128.42M derived: sum of 3 quarters · filed 2024-02-27 | -$174.63M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$40.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$76.72M derived: sum of 2 quarters · filed 2022-11-08 | -$122.92M 10-Q · filed 2022-11-08 | -$155.49M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$35.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$82.03M 10-Q · filed 2022-08-04 | -$114.61M derived: sum of 3 quarters · filed 2023-02-28 | -$148.30M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$46.20M 10-Q · filed 2022-05-05 | -$78.77M derived: sum of 2 quarters · filed 2023-02-28 | -$112.47M derived: sum of 3 quarters · filed 2023-02-28 | -$138.23M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$32.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$66.26M derived: sum of 2 quarters · filed 2023-02-28 | -$92.02M derived: sum of 3 quarters · filed 2023-02-28 | -$113.03M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$33.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$59.45M derived: sum of 2 quarters · filed 2021-11-04 | -$80.46M 10-Q · filed 2021-11-04 | -$97.26M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | -$25.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$46.77M 10-Q · filed 2021-08-05 | -$63.57M derived: sum of 3 quarters · filed 2022-02-22 | -$74.29M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | -$21.01M 10-Q · filed 2021-05-06 | -$37.81M derived: sum of 2 quarters · filed 2022-02-22 | -$48.53M derived: sum of 3 quarters · filed 2022-02-22 | -$56.77M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | -$16.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | -$27.52M derived: sum of 2 quarters · filed 2022-02-22 | -$35.76M derived: sum of 3 quarters · filed 2022-02-22 | -$42.84M 10-K · filed 2022-02-22 |
| 2019-09-30 | -$10.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$18.96M derived: sum of 2 quarters · filed 2020-11-05 | -$26.04M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$8.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$15.32M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | -$7.07M 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | -$14.09M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |